Navitoclax (ABT-263)
Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
Data Science for Genomics2023, 107-128.
Eur J Pharmacol.2018, 832:96-103
J Sep Sci.2020, 201901140
Inflammation.2021, doi: 10.1007
Applied Biological Chemistry 2022, 65,5(2022).
Chemistry of Plant Materials.2019, 215-222
Am J Chin Med.2016, 44(8):1719-1735
Korean Journal of Pharmacognosy2017, 48(4):320-328
Eur J Pharmacol.2021, 906:174220.
Biochem Pharmacol.2017, 130:10-20
Related and Featured Products
Clin Cancer Res, 2008 Jun 1;14(11):3268-77.
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models.[Pubmed:
18519752]
The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models.
METHODS AND RESULTS:
A panel of 11 SCLC xenograft models was established to evaluate the efficacy of ABT-263. Single agent activity was examined on a continuous dosing schedule in each of these models. The H146 model was used to further evaluate dose and schedule, comparison to standard cytotoxic agents, and induction of apoptosis.
ABT-263 exhibited a range of antitumor activity, leading to complete tumor regression in several models. Significant regressions of tumors as large as 1 cc were also observed. The efficacy of ABT-263 was also quite durable; in several cases, minimal tumor regrowth was noted several weeks after the cessation of treatment. Antitumor effects were equal or superior to that of several clinically approved cytotoxic agents. Regression of large established tumors was observed through several cycles of therapy and efficacy was retained in a Pgp-1 overexpressing line. Significant efficacy was observed on several dose and therapeutic schedules and was associated with significant induction of apoptosis.
CONCLUSIONS:
ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials. The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent.
Cancer Res,2008 May 1;68(9):3421-8.
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.[Pubmed:
18451170]
Cell lines:SCLC cell lines
Concentrations: 0-1 μM
Incubation Time: 48 hours
Method:
Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.
Cancer Res, 2008 May 1;68(9):3421-8.
ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.[Pubmed:
18451170]
Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
Dosages:100 mg/kg/d
Administration: Administered via p.o.
